LBLeti van Bodegom-Vos

Leti van Bodegom-Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leti van Bodegom-Vos has a total of 423 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of severe functional limitations and physical therapy use in patients with rheumatoid arthritis or axial spondyloarthritis: a multicentre cross-sectional study in the Netherlands

    by Ar Iken, L van Bodegom-Vos, Tpm Vliet Vlieland, Fa van Gaalen, Am van Tubergen, Wh Noort-Van der Laan, Rw Poolman, Mgj Gademan, for the L-EXTRA/L-EXSPA Implementation Group

    Recent evidence supports the (cost-)effectiveness of a personalized, long-standing exercise intervention for people with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) with severe fun...

  • Open Access

    Surgeon's treatment outcome prediction: accuracy and communication

    by Lisa Vlug, Ellen C. de Lange, Anouk A. Kruiswijk, Arwen H. Pieterse, Yvonne M. Schrage, Michiel A.J. van de Sande, Leti van Bodegom-Vos, Rick L. Haas, Cornelis Verhoef, Marc Ha. Bemelmans, et al.

  • Open Access

    Attitudes and Practices Regarding Dosing Interval Extension of Biologics in Severe Asthma: A Nationwide Survey and Real-World Data From the Dutch RAPSODI Registry

    by Camiel J.M. Marijnissen, Jacob K. Sont, Fleur L. Meulmeester, Michel W.J.M. Wouters, Gert-Jan Braunstahl, Arnoud F. Aldenkamp, Simone Hashimoto, Johannes A. Kroes, M. Elske van Den Akker-Van Marle, Ewout W. Steyerberg, et al.

  • Open Access

    Identifying and addressing UTI prevention barriers in primary care: a qualitative study

    by Merel Ep Wilmsen, Laurens C van Gestel, Martijn Sijbom, Ashty Koucher, Marjan J Aantjes, Leti van Bodegom-Vos, Rimke C Vos, Tobias N Bonten, Marieke A Adriaanse, Suzanne E Geerlings, et al.

    Background: Urinary tract infection (UTI) recurrence rates are high for certain patient groups, affecting physical and mental health, and leading to repeated antibiotic usage. Behavioural measures and non-antibiotic products can prevent recurrences, reducing the need for antibiotics. However, these preventive strategies are often not addressed, despite being advocated in UTI guidelines. Aim: To identify barriers to and facilitators of discussing UTI prevention in primary care and to identify strategies to overcome these barriers. Design & setting: Qualitative study in a primary care setting. Method: Semi-structured interviews were performed with GPs, doctor’s assistants, and patients with a history of UTI to identify barriers to and facilitators of discussing UTI prevention. Deductive content analysis was employed, using the Theoretical Domains Framework to structure the interview guide and analyse the data. Subsequent focus groups were performed to identify strategies to overcome the barriers. Results: Main barriers for all stakeholders included incomplete knowledge, prioritisation of treatment over prevention, and time pressure at the general practice. Additionally, general practices lacked protocols on when, which, and by whom preventive measures should be discussed. Healthcare professionals also assumed patients already held preventive knowledge and solely sought care to obtain antibiotics. The main facilitator was patient-initiated conversations about UTI. Strategies included enhancing knowledge, inviting patients to initiate conversations about UTI, and optimising the timing of preventive information dissemination. Conclusion: Barriers exist across behavioural, interpersonal, and organisational domains, but provide clear starting points for tailored interventions. The strategies offer promising directions for improving UTI prevention and reducing antimicrobial consumption.

  • Open Access

    Improving support for family caregivers in palliative care through journey mapping: a qualitative study across 19 healthcare organizations

    by Arianne Stoppelenburg, Hinke E. Hoffstädt, Leti van Bodegom-Vos, Willemijn Boere, Esmée Wiemans, Marcella C. Tam, Iris D. Hartog, Marieke H. Sonneveld, Jenny T. van der Steen, Yvette M. van der Linden

    Background / aim: Family caregivers play a crucial role in supporting and caring for patients with life-threatening diseases. Providing this care can be rewarding but can also pose a great burden on family caregivers. Therefore, support is needed to address their problems and needs. However, systematic support for family caregivers is often lacking within healthcare organizations. To bridge this gap, a Family Caregiver Journey Workshop was developed as an implementation tool to help healthcare organizations enhance structural support for family caregivers. The aim of this study was to investigate the output of this workshop and to evaluate its process . Methods: The workshop was conducted in 19 healthcare organizations (7 home care organizations, 6 hospices, 3 nursing homes, 2 hospitals, 1 transmural organization). Each organization assembled a group of healthcare professionals to conduct the workshop and develop an action plan based on its outcomes. Subsequently, a focus group with participants from different organizations was held to evaluate their experiences with the workshop. The action plans and the focus group transcript were analyzed using conventional content analysis. Results: The action plans described various goals, activities, timelines and responsibilities. Goals focused on (1) direct support for family caregivers and (2) preconditions on the team and organizational level. Planned activities for family caregivers included systemically addressing their needs and wellbeing, improving information provision, supporting their involvement in patient care, strengthening patient-caregiver relationships, and offering bereavement support. Activities at the team or organizational level included developing protocols, guidelines and tools, providing training and education, fostering interprofessional collaboration, and supporting healthcare professionals. Healthcare professionals across all healthcare settings considered the workshop a useful tool to reflect on current practices and identify concrete improvements in supporting family caregivers. Conclusion: The Family Caregiver Journey Workshop is a valuable implementation tool for healthcare professionals to reflect on their current practice of supporting family caregivers and to set targeted improvement goals. Trial registration: Open Science Framework (OSF), preregistration 2022: Supporting family caregivers during the illness and after the death of their loved one, with special attention for individual needs, health skills and culturally sensitive communication . https://osf.io/57wm9/overview


  • Open Access

    Evaluating the effectiveness of a risk prediction model (PERSARC) on improving treatment decisions quality for patients with soft-tissue sarcomas: the VALUE-PERSARC study

    by Anouk A. Kruiswijk, Perla J. Marang-Van de Mheen, Lisa A. E. Vlug, Ellen G. Engelhardt, Marta Fiocco, Rick L. Haas, Yvonne M. Schrage, Cornelis Verhoef, Marc H. A. Bemelmans, Robert J. van Ginkel, et al.

    Risk prediction models (RPM) can potentially improve treatment decisions by providing personalized survival estimates for different treatment options, but their effectiveness is uncertain. The VALUE-PERSARC study evaluated the impact of the PERsonalised SARcoma Care (or PERSARC) RPM on decision-making quality in patients with high-grade extremity soft tissue sarcomas (STS). A parallel cluster randomized controlled trial was conducted in seven Dutch hospitals, assigned to usual care (control) or care with PERSARC (intervention). PERSARC supported treatment recommendations and informed patients about personalized risks and relevant treatment options. The primary outcome was decision-making quality, measured by patients’ knowledge of treatment risks and benefits and decisional conflict (Decisional Conflict Scale). Secondary outcomes included the Cancer Worry Scale (CWS), Shared Decision-Making (SDM-Q9), number of treatment options discussed and treatment choice. This study enrolled 120 patients: 53 patients in the control group and 67 patients in the intervention group. No significant differences were observed between the control and intervention groups in patients’ adequate knowledge (respectively 82% vs. 86%) and decisional conflict (respectively 23.1 [15.5] vs. 18.9 [12.8]). Scores on the CWS (11.7 [3.3] vs. 11.0 [3.5]) and SDM-Q9 (13.3 [4.0] vs. 15.6 [3.3]) were also similar. Treatment choices did not differ significantly between groups. However, clinicians in the intervention group were significantly more likely to discuss multiple treatment options (93% vs. 35%). While PERSARC did not significantly improve patients’ knowledge or decisional conflict, it led to more frequent discussion of multiple treatment options by clinicians. This may be an important step towards enhancing shared decision-making in practice. Trail registration: The VALUE-PERSARC study was registered on January 8, 2021 in the Netherlands Trial Register (NL9160) and updated on January 23, 2023 in ClinicalTrials.gov (NCT05741944). The VALUE-PERSARC study was initially registered in the Netherlands Trial Register (NL9160) on January 8, 2021, and subsequently updated in ClincicalTrials.gov (NCT05741944) on January 31, 2023.


  • Open Access

    Improving support for family caregivers: a mixed-methods effect evaluation of an organizational intervention

    by Hinke E. Hoffstädt, Arianne Stoppelenburg, Marcella C. Tam, Iris D. Hartog, Leti van Bodegom-Vos, Bart J.A. Mertens, Jenny T. van der Steen, Yvette M. van der Linden

    Objectives To evaluate the impact of a tailored organizational intervention on the support for family caregivers. Methods A convergent mixed-methods study was conducted in 17 organizations (6 hospices, 5 home care organizations, 3 nursing homes, 2 hospitals, 1 transmural organization) between November 2021 and August 2023. The intervention comprised a quality improvement trajectory during which each organization conducted a structured workshop to define organization-specific goals to improve their support for family caregivers and to develop an action plan to achieve those goals. The action plan was implemented over one year with intermittent evaluations. Pre and post-intervention surveys were distributed among healthcare professionals (paired) and bereaved family caregivers (non-paired) to assess provided and received support. Data were analyzed with mixed models and regression analyses. Post-intervention focus groups with project team members and final evaluation reports were analyzed with qualitative content analysis. Results Survey respondents were 97 healthcare professionals (83% nursing staff), 123 family caregivers pre-intervention and 99 family caregivers post-intervention. Only healthcare professionals of home care organizations reported a significant increase in attending to family caregivers’ wellbeing and needs (scale 0-20; β=3.65; 95%CI: 1.33-5.97). Family caregivers’ reports of healthcare professionals attending to their wellbeing and needs did not change (scale 0-2; β=0.17; 95%CI: -0.04-0.38). Across settings, healthcare professionals evaluated the care they provided more positively post-intervention (scale 0-8; β=0.65, 95%CI: 0.38-0.97). In home care, family caregivers also evaluated care more positively (scale 0-8; β=2.12; 95%CI: 0.89-3.34). Four focus groups and 17 evaluation reports indicated improvements at three levels: the support for family caregivers (increased awareness of healthcare professionals, changes in work processes, more structured support), the healthcare team (more skills, confidence, available tools) and the organization (fostering sustainability). Significance of results A tailored organizational intervention can strengthen the supporting of family caregivers in healthcare organizations.

  • Open Access

    Systemic treatment decisions in older patients with early invasive breast cancer: Evidence and strategies

    by Julia N. Wolbink, Leti van Bodegom-Vos, Erik J. Blok, Johanneke E. A. Portielje

    The treatment of early invasive breast cancer in older patients poses unique challenges due to the distinct biological, clinical, and psychosocial complexities associated with aging. As the population of breast cancer patients aged 70 years and older continues to grow, their persistent underrepresentation in clinical trials remains a major obstacle to evidence-based treatment decision-making. To support the development of a more effective, personalized, and patient-centered approach to systemic therapy, this review outlines the biological features of breast cancer in older women, synthesizes current evidence on neoadjuvant and adjuvant systemic therapies, and discusses strategies for individualized treatment decision-making. Key recommendations include the use of hormonal therapy as the standard of care for hormone receptor positive breast cancer, neoadjuvant therapy primarily when tumor downstaging is desired, and chemotherapy or anti-human epidermal growth factor receptor 2 therapy for relatively fit older patients with high-risk subtypes. Additionally, bisphosphonates may help preserve bone health and reduce recurrence risk. Novel targeted therapies such as cyclin-dependent kinase 4 and 6 inhibitors and immune checkpoint inhibitors show promise, though further studies are needed to confirm their safety and efficacy in older populations. Comprehensive geriatric assessments are essential for identifying patient frailty and vulnerabilities, while predictive tools such as the Cancer and Aging Research Group Breast Cancer model can help assess toxicity risk. In this population, competing risks of non-cancer-related mortality may reduce the absolute benefit of systemic treatment. For patients with elevated risks of other-cause mortality, the potential survival benefit of cancer therapy may be negligible. Predictive models that account for competing mortality, such as the PORTRET tool, can facilitate personalized and shared decision-making.


  • Open Access

    ASO Author Reflections: Enhancing Shared Decision-Making with Risk Prediction Models in Sarcoma Care

    by Leti van Bodegom-Vos, Anouk Kruiswijk, Michiel van de Sande


  • Integrated oncological treatment decision-making: Creating a practice of patient-centred decision-making

    by Hanneke van der Wal-Huisman, Barbara L. van Leeuwen, Anne M. Stiggelbout, Floor M. van Nuenen, Trudy van der Weijden, Suzanne Festen, Lieke Welling, L.L. van Baalen, V.C. Hanewinkel, J. Jansen, et al.